BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 234 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.15 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $3,551,877 | -15.6% | 504,528 | 0.0% | 0.14% | -13.1% |
| Q1 2023 | $4,207,764 | -45.5% | 504,528 | -25.0% | 0.16% | -45.2% |
| Q4 2022 | $7,722,653 | +75.3% | 672,705 | +92.4% | 0.29% | +62.2% |
| Q3 2022 | $4,405,000 | +50.1% | 349,570 | +26.0% | 0.18% | +56.5% |
| Q2 2022 | $2,935,000 | -8.2% | 277,434 | +41.1% | 0.12% | +2.7% |
| Q1 2022 | $3,197,000 | +44.9% | 196,625 | -56.2% | 0.11% | +31.8% |
| Q4 2017 | $2,206,000 | +30.2% | 449,255 | +39.0% | 0.08% | +39.3% |
| Q3 2017 | $1,694,000 | – | 323,255 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 3,846,154 | $27,230,770 | 26.28% |
| Prosight Management, LP | 2,408,135 | $17,049,596 | 5.40% |
| Kynam Capital Management, LP | 3,133,193 | $22,183,006 | 3.63% |
| Saturn V Capital Management LP | 982,458 | $6,955,803 | 2.91% |
| AlphaCentric Advisors LLC | 649,000 | $4,594,920 | 2.61% |
| TANG CAPITAL MANAGEMENT LLC | 1,800,000 | $12,744,000 | 1.80% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 791,671 | $5,605,031 | 1.70% |
| Eversept Partners, LP | 2,479,103 | $17,552,049 | 1.48% |
| DAFNA Capital Management LLC | 652,000 | $4,616,160 | 1.44% |
| Avoro Capital Advisors LLC | 11,550,000 | $81,774,000 | 1.28% |